Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
synthetic cannabinoid
|
| gptkbp:actsOn |
CB1 receptor agonist
CB2 receptor agonist |
| gptkbp:CASNumber |
209414-07-3
|
| gptkbp:category |
gptkb:naphthoylindole
recreational drug CB1 receptor agonist CB2 receptor agonist synthetic cannabinoid |
| gptkbp:chemicalFormula |
C24H23NO
|
| gptkbp:discoveredBy |
gptkb:John_W._Huffman
|
| gptkbp:excretion |
kidneys
|
| gptkbp:firstSynthesized |
1995
|
| gptkbp:hasSMILES |
CCCCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43
|
| https://www.w3.org/2000/01/rdf-schema#label |
JWH-018
|
| gptkbp:IUPACName |
1-pentyl-3-(1-naphthoyl)indole
|
| gptkbp:legalStatus |
illegal in many countries
Schedule I controlled substance in the United States Class B drug in the United Kingdom |
| gptkbp:marketedAs |
gptkb:spice
K2 |
| gptkbp:meltingPoint |
162–166 °C
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
341.45 g/mol
|
| gptkbp:namedAfter |
gptkb:John_W._Huffman
|
| gptkbp:PubChem_CID |
20941407
|
| gptkbp:relatedTo |
gptkb:HU-210
gptkb:JWH-073 gptkb:JWH-122 gptkb:AM-2201 |
| gptkbp:routeOfAdministration |
oral
inhalation |
| gptkbp:sideEffect |
nausea
vomiting anxiety hypertension paranoia psychosis seizures tachycardia hallucinations agitation |
| gptkbp:UNII |
K2CYN6F2V5
|
| gptkbp:used_in |
herbal incense blends
|
| gptkbp:usedFor |
recreational drug
research chemical |
| gptkbp:bfsParent |
gptkb:JWH_cannabinoids
|
| gptkbp:bfsLayer |
6
|